TRPM2 and gastric cancer: It has been reported that cytoplasmic TRPM2-AS can act as a promoter of cancer in GC by competitively binding to miRNAs (Huang et al. 2019).This suggests that the lncRNA TRPM2-AS is capable of facilitating the progression of GC and enhancing its resistance to radiotherapy (Xiao et al. 2020).